跳转至内容
Merck
CN

T2705

拓扑替康 盐酸盐 水合物

≥98% (HPLC and enzymatic), powder, topoisomerase I inhibitor

别名:

9-[（二甲基氨基）甲基]-10-羟基-（20S）-喜树碱 盐酸盐 水合物, NSC-609669 盐酸盐 水合物, SKF-104864A 盐酸盐 水合物, 拓扑替康 盐酸盐 水合物

登录 查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C23H23N3O5 · xHCl · yH2O
化学文摘社编号:
123948-87-8
分子量:
421.45 (anhydrous free base basis)
MDL编号:
MFCD00870670
UNSPSC代码:
12352200
PubChem化学物质编号:
329826724
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

拓扑替康 盐酸盐 水合物, ≥98% (HPLC and enzymatic)

方案

≥98% (HPLC and enzymatic)

表单

powder

储存条件

desiccated
protect from light

颜色

yellow

溶解性

DMSO: ≥20 mg/mL

创始人

GlaxoSmithKline

储存温度

−20°C

SMILES字符串

[n]21c(cc5c([c]2=O)COC(=O)[C@]5(O)CC)c3nc4c(cc3C1)c(c(cc4)O)CN(C)C

InChI

1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1

InChI key

UCFGDBYHRUNTLO-QHCPKHFHSA-N

基因信息

human ... TOP1MT(116447)

相关类别

应用

拓扑替康作为阳性对照，已被用作低氧条件下人神经胶质瘤细胞中HIF-1α 和VEGF抑制剂的鉴定和分析1。它也被用于 体外 PA317细胞的凋亡检测2。

生化/生理作用

拓扑替康是一种拓扑异构酶I抑制剂和凋亡诱导剂。它是一种有效的抗肿瘤药。

特点和优势

该化合物由GlaxoSmithKline开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。
这种化合物是ADME毒性和凋亡研究的特色产品。发现更多有关ADME毒性 和 凋亡 的特色产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

制备说明

本品可溶于水，但浓度尚未确定。但多条来源表明，这种化学品在水中的溶解度大于 1 mg/mL。
水合盐酸拓扑替康可溶于DMSO，溶解浓度大于等于20 mg/ml。

象形图

Health hazard
GHS08

警示用语：

Danger

危险声明

H340,H361d

危险分类

Muta. 1B - Repr. 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000314301
0000314301
0000239575
0000218334
0000239575

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Jerec W Ricci et al.
Molecular cancer therapeutics, 15(12), 2853-2862 (2016-09-28)
Chemotherapeutic resistance remains a challenge in the treatment of ovarian carcinoma, especially in recurrent disease. Despite the fact that most patients with newly diagnosed tumors attain complete remission following cytoreductive surgery and chemotherapy, ovarian carcinoma has a recurrence rate that
Andrei Molotkov et al.
Pharmaceutics, 13(3) (2021-04-04)
Glioblastoma (GBM) is the most common primary adult brain malignancy with an extremely poor prognosis and a median survival of fewer than two years. A key reason for this high mortality is that the blood-brain barrier (BBB) significantly restricts systemically
Iben Kümler et al.
Breast cancer research and treatment, 138(2), 347-358 (2013-03-21)
Following treatment with anthracyclines and taxanes, few established options exist for the treatment of metastatic breast cancer (MBC). Although the topoisomerase 1 inhibitors irinotecan, etirinotecan, and topotecan have been used in clinical trials on MBC, the drugs have never been
Ian F King et al.
Nature, 501(7465), 58-62 (2013-09-03)
Topoisomerases are expressed throughout the developing and adult brain and are mutated in some individuals with autism spectrum disorder (ASD). However, how topoisomerases are mechanistically connected to ASD is unknown. Here we find that topotecan, a topoisomerase 1 (TOP1) inhibitor
Kaleem Ashraf et al.
Pediatric blood & cancer, 60(10), 1636-1641 (2013-05-08)
Reports of responses and toxicities of salvage therapies for relapsed neuroblastoma are rare and often confounded by effects of additional treatments. Our objective was to describe the outcomes and toxicities for a topotecan and cyclophosphamide (TOPO/CTX) regimen for first relapse
查看所有相关文献

商品

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Bioactive Molecules for Apoptosis

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持